• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GlucoTrack And 2 Other Stocks Under $1 Insiders Are Buying

    4/25/24 9:03:43 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care
    Get the next $GCTK alert in real time by email

    The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Tecogen

    • The Trade: Tecogen Inc. (OTC:TGEN) Director Earl R Lewis bought a total of 10,000 shares at an average price of $0.68. To acquire these shares, it cost around $6,800. The company's Director John Hatsopoulos also bought 5,000 shares.
    • What's Happening: Tecogen is expected to release first-quarter financial results on Thursday, May 9.
    • What Tecogen Does: Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services, and Energy Production.

    Bespoke Extracts

    • The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod acquired a total of 5,000 shares at an average price of $0.11. To acquire these shares, it cost around $550.
    • What's Happening: The company's stock lost around 22% over the past six months.
    • What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.

    GlucoTrack

    • The Trade: GlucoTrack, Inc. (NASDAQ:GCTK) Director Drew Sycoff acquired a total of 182,540 shares at an average price of $1.26. The insider spent around $230,000 to buy those shares.
    • What's Happening: GlucoTrack recently announced closing of private placement.
    • What GlucoTrack Does: GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics.

    Check This Out: Jim Cramer Says This Energy Stock Is ‘Terrific,’ Calls Casey’s General Stores A ‘Winner’

    Get the next $GCTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GCTK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GCTK
    SEC Filings

    View All

    SEC Form DEF 14A filed by GlucoTrack Inc.

    DEF 14A - Glucotrack, Inc. (0001506983) (Filer)

    2/9/26 4:05:32 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by GlucoTrack Inc.

    PRE 14A - Glucotrack, Inc. (0001506983) (Filer)

    1/29/26 5:17:06 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    GlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Glucotrack, Inc. (0001506983) (Filer)

    1/29/26 9:24:21 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

    RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company's continuous blood glucose monitoring (CBGM) platform. The patents strengthen Glucotrack's competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization. The three patents protect key technologies in Glucotra

    1/29/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

    Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) (the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at an effective combined price of $3.87 per share and common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fees and other offer

    12/30/25 8:00:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sycoff Drew bought $230,000 worth of shares (182,540 units at $1.26), increasing direct ownership by 7% to 2,951,258 units (SEC Form 4)

    4 - GlucoTrack, Inc. (0001506983) (Issuer)

    4/24/24 6:31:49 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Carr Brendel Victoria

    3 - Glucotrack, Inc. (0001506983) (Issuer)

    10/7/25 9:57:31 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Director Balo Andrew K was granted 4,692 shares (SEC Form 4)

    4 - Glucotrack, Inc. (0001506983) (Issuer)

    10/7/25 9:38:38 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Director Malave Luis was granted 1,698 shares, increasing direct ownership by 72% to 4,058 units (SEC Form 4)

    4 - Glucotrack, Inc. (0001506983) (Issuer)

    10/7/25 9:06:05 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Leadership Updates

    Live Leadership Updates

    View All

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

    RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been named to Glucotrack's clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM). "Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain man

    10/29/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025 Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board Improved capital structure, cash and cash equivalents expected to fund operations through 2025, including initiation of OUS clinical trials and achievement of related milestones Rutherford, NJ, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focu

    8/14/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Financials

    Live finance-specific insights

    View All

    GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

    1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock (the "Common Stock"), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number

    5/15/24 4:15:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GlucoTrack Inc.

    SC 13G - Glucotrack, Inc. (0001506983) (Subject)

    9/10/24 1:32:03 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by GlucoTrack Inc.

    SC 13G - GlucoTrack, Inc. (0001506983) (Subject)

    1/3/24 1:54:20 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care